Roche says its new interim update on hemophilia A drug is positive. But it’s hard to gauge.
Roche today sent out a small, blurry snapshot of the interim data from a Phase III study of emicizumab in children suffering from hemophilia A.
What did we find out?
The data are positive and “clinically meaningful” — though presumably not statistically significant, which is the phrase you look for in determining success or failure — in cutting the bleed rate among children 12 or younger with inhibitors to Factor VIII.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.